Type 2 diabetes
Conditions
Interventions
A Group:Sequence 1: Glucose - reduced sugar priority sequence (or reduced sugar mode priority sequence).
Sequence 2: Glucose - regular priority sequence (or regular mode priority sequence). The washo
Group B :Sequence 1: Glucose - reduced sugar priority order (or reduced sugar mode priority order) Sequence 2: Glucose - regular priority order (or regular mode priority order). The washout period bet
Sponsors
Shanghai Tongren Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Group A 1. Age 18-60, any gender, healthy, no serious underlying conditions (like diabetes, high blood pressure, gastrointestinal diseases, etc.); 2. BMI 18.5-24.9 kg/m^2, normal body shape, not noticeably overweight or underweight; 3. Fasting blood glucose 3.9~-=6.1 ~ 6.9 mmol/L, and 2-hour blood glucose in the OGTT between 7.8 ~ 11.0 mmol/L, indicating decreased regulation of glucose, belonging to the impaired glucose tolerance group; 4. In the past 3 months, no intake of any supplements affecting glucose tolerance, and no use of protease inhibitors, contraceptives, aspirin, antidepressants or psychiatric drugs, steroids, or other medications that affect glucose tolerance; 5. Regular diet over the past 3 months, no special eating habits (like long-term vegetarianism or high-sugar diet), and no intake of medications or health supplements affecting blood glucose metabolism; 6. Willing to participate in the trial, signed informed consent, able to strictly follow trial procedures and complete all trial sessions on time; 7. No history of rice or glucose allergies.
Exclusion criteria
Exclusion criteria: Group A 1. Currently pregnant, breastfeeding, or planning to become pregnant during the study period; 2. Having blood sugar-related conditions such as diabetes, impaired glucose tolerance, hypoglycemia, or a family history of diabetes; 3. Having gastrointestinal, liver, kidney, or other diseases that affect nutrient absorption or metabolism; 4. Taken medications in the past month that might affect the study results, such as glucose-lowering drugs, hormones, or antibiotics; 5. History of smoking or alcohol addiction, or unable to quit smoking or drinking during the study; 6. Used insulin in the past 3 months; 7. Donated blood or experienced blood loss = 400mL within 8 weeks before the study starts; 8. Infected with HIV-1 or having malignant tumors; 9. Recent (within 4 weeks) acute respiratory symptoms; 10. Having an allergic constitution or being allergic to multiple drugs; 11. Having disrupted circadian rhythms, like shift workers; 12. Poor compliance, unable to cooperate to complete the study, or likely to drop out midway; taken antibiotics within a month before participating; 13. Having systemic diseases (like blood disorders, liver diseases, severe diabetes, etc.); 14. Known allergy or intolerance to Japonica or Indica rice; 15. Other populations that the researcher thinks are not eligible for the clinical trial. Group B 1. Currently pregnant, breastfeeding, or planning to become pregnant during the trial period; 2. Have gastrointestinal, liver, kidney, or other diseases that affect nutrient absorption or metabolism; 3. Took medications in the past month that might affect trial results, such as anti-diabetic drugs, hormones, or antibiotics; 4. Have a history of smoking or alcohol addiction, or cannot quit smoking or drinking during the trial; 5. Used insulin in the past 3 months; 6. Donated blood or lost >= 400mL of blood within 8 weeks prior to the trial; 7. HIV-1 infection or malignant tumors; 8. Recent (within 4 weeks) acute respiratory symptoms; 9. Allergy-prone or allergic to multiple drugs; 10. Circadian rhythm disorders, such as shift workers; 11. Poor compliance, unable to complete the trial process, or likely to withdraw mid-trial. Took antibiotics in the month before joining the study; 12. Have systemic diseases (such as blood disorders, liver diseases, severe diabetes, etc.); 13. Known allergy or intolerance to japonica or indica rice; 14. Other populations that the researcher considers unsuitable for participating in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycemic Index (GI); | — |
Secondary
| Measure | Time frame |
|---|---|
| Incremental area under the post-meal blood sugar curve (iAUC);Blood sugar peak, peak time, blood sugar fluctuations;Product Satisfaction Survey; | — |
Countries
China
Contacts
Public ContactHuang Shan
Shanghai Tongren Hospital
Outcome results
None listed